Maxion Therapeutics Secures Key Investment in KnotBody Technology Growth

Deal News | Mar 17, 2025 | British Business Bank Investments Ltd

British Patient Capital, a subsidiary of the British Business Bank, has invested £10 million in Maxion Therapeutics as part of a £58 million Series A funding round led by General Catalyst. The round also attracted investments from new contributors Solasta Ventures and Eli Lilly and Company, alongside existing investors LifeArc Ventures, Monograph Capital, and BGF. The funding is aimed to support the development of Maxion's unique KnotBody technology designed for ion channel and GPCR-related diseases like inflammatory and cardiovascular diseases. This novel technology could address the limitations of current small molecule drugs by offering improved selectivity and therapeutic efficacy. The financing will help advance the company's lead KnotBody program, MAX001, to clinical proof of concept. New board members, including representatives from General Catalyst and British Patient Capital, will join as a result of this round.

Sectors

  • Biotechnology
  • Pharmaceuticals
  • Venture Capital

Geography

  • United Kingdom – British Patient Capital and Maxion Therapeutics are based in the UK, making it a geographic focus of the investment.
  • Global – The nature of biotechnology and pharmaceuticals being developed by Maxion Therapeutics targets global markets with their innovative solutions.

Industry

  • Biotechnology – Maxion Therapeutics is a biotechnology company focused on developing therapies for diseases driven by ion channel and GPCR dysfunction.
  • Pharmaceuticals – The company's work in developing antibody-based treatments for inflammatory and cardiovascular diseases places it within the pharmaceutical industry.
  • Venture Capital – The article discusses a significant investment by venture capital entities into Maxion Therapeutics as part of a Series A funding round.

Financials

  • £58 million – Total Series A financing round amount raised by Maxion Therapeutics.
  • £10 million – Investment amount by British Patient Capital in Maxion Therapeutics.

Participants

NameRoleTypeDescription
Maxion TherapeuticsTarget CompanyCompanyA biotechnology company developing KnotBody drugs targeting ion channel and GPCR-driven diseases.
British Patient CapitalInvestorCompanyA commercial subsidiary of the British Business Bank investing in later-stage growth companies.
General CatalystLead InvestorCompanyA venture capital firm that led the Series A round for Maxion Therapeutics.
Solasta VenturesInvestorCompanyNew investor participating in the Series A round for Maxion Therapeutics.
Eli Lilly and CompanyInvestorCompanyA global pharmaceutical company partaking in the investment round for Maxion.
LifeArc VenturesInvestorCompanyAn existing investor in Maxion that supported the new funding round.
Monograph CapitalInvestorCompanyAn existing investor contributing to Maxion's Series A financing.
BGFInvestorCompanyA former investor in Maxion Therapeutics participating in the latest funding.
Dr. John McCaffertyCo-founderPersonCo-founder of Maxion Therapeutics involved in technology development.
Dr. Aneesh Karatt-VellattCo-founderPersonCo-founder of Maxion Therapeutics who developed the KnotBody technology.
Elena VibochBoard MemberPersonManaging Director at General Catalyst joining Maxion's board post-investment.
Emma JohnsonBoard MemberPersonSenior Investment Manager at British Patient Capital appointed to Maxion's board.
Arndt Schottelius, MD PhDChief Executive OfficerPersonCEO of Maxion Therapeutics.